Pro-Pharmaceuticals and Sanghyon sign agency agreement

Sanghyon Chemical will provide for the registration of Davanat with the Korean FDA and marketing and sales support for the licensing and distribution of Davanat to treat cancer with chemotherapy drugs.

Theodore Zucconi, president of Pro-Pharmaceuticals, said: “The collaboration with Sanghyon Chemical is another step in the realization of commercializing Davanat on a regional basis.

“We continue to pursue partnerships with regional distributors who understand how to do business in their regions, as well as with several large international pharmaceutical companies. Sanghyon is an experienced partner that will enable us to penetrate a major market such as Korea.”